Sector News

Pfizer lures first chief marketing officer from Verily

September 3, 2022
Life sciences

Pfizer is hiring an Alphabet life sciences executive as its first global chief marketing officer, the third major addition to its senior ranks this year.

Drew Panayiotou, chief marketing officer of Alphabet’s life sciences research arm Verily, will join Pfizer on Sept. 19. He will be responsible for building commercial infrastructure including “new innovative engagement channels, tools, and digital solutions,” Pfizer said in an emailed statement. He will report to Angela Hwang, head of Pfizer’s biopharmaceuticals unit.

The announcement comes about six months after two retirements led to a reshuffling of Pfizer’s senior ranks, amid a surge in revenue to record levels from sales of its COVID-19 vaccine and antiviral drug. Pfizer hired William Pao as chief development officer from Roche in February and David Denton as chief financial officer from Lowe’s in April.

Pfizer is familiar with Verily through a partnership it, along with three other pharmas, signed with the technology company in 2019 to tap its data tools for clinical studies.

Panayiotou was also the first chief marketing officer at Verily. He has more than 30 years experience in marketing, previously working at Johnson & Johnson, Coca-Cola and Disney, among others. At Pfizer, he joins a company whose business dwarfs most others in the pharma sector, after its first-half revenues surged by 60% and are on track to reach about $100 billion for the first time.

“Drew’s insights and diverse thinking will help us elevate the cutting-edge customer channels, skills and capabilities we need to deliver” new medicines to patients, Hwang said in a LinkedIn post.

By Christopher Newman

Source: biopharmadive.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.